Although the clinical data reveal no evidence that SGLT2 inhibitors reduce the number of cardiovascular events such as acute coronary syndromes, they may reduce the myocardial injury that occurs as a consequence of these events. The gene discussed is SLC5A2; the disease is acute coronary syndrome.